SQLite Web: event_store.db

Update row sig_f4bdb00d0e68 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/healthcare-stock-millionaire-maker","as_of":"2026-04-08T22:43:46.053448+00:00","canonical_url":"https://www.fool.com/investing/2026/04/08/is-this-healthcare-stock-a-millionaire-maker/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/healthcare-stock-millionaire-maker","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_c3d78b486074a5fe","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/08/is-this-healthcare-stock-a-millionaire-maker/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-09T23:24:01.176727+00:00","extraction_method":"heuristic","fetched_description":"Key PointsAxsome Therapeutics has performed well since its IPO.","fetched_title":"Is This Healthcare Stock a Millionaire Maker? | Nasdaq","final_url":"https://www.nasdaq.com/articles/healthcare-stock-millionaire-maker","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/healthcare-stock-millionaire-maker","source_event_id":"evt_46131abf8cf6","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"9f5403b5f5b3291d","kind":"unusual_volume","published_at":"2026-04-08T22:08:28+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["April 08, 2026"],"entities":[{"asset_class":"equity","name":"Axsome Therapeutics","relevance":"high","symbol":"AXSM","type":"company"},{"asset_class":"unknown","name":"The Motley Fool","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"unknown","name":"Auvelity","relevance":"high","symbol":"","type":"product"},{"asset_class":"equity","name":"Nvidia","relevance":"low","symbol":"NVDA","type":"company"},{"asset_class":"equity","name":"Intel","relevance":"low","symbol":"INTC","type":"company"}],"event_type":"other","information_gaps":["Signal type is discovery_unusual_volume_delta, but the provided text contains no trading-volume data, no volume ratio vs average, and no direction (e.g., above/below average).","No ticker is explicitly tied to an unusual volume event in the provided text; AXSM is mentioned as the subject of the article.","No catalyst is described as the cause of any volume spike; the article discusses general growth catalysts (pipeline, label expansion) but does not link them to unusual volume.","No confirmation mechanism (e.g., news-driven volume vs unexplained) is provided for any volume anomaly."],"key_facts":["Axsome Therapeutics (NASDAQ: AXSM) went public in 2015.","The article states that investing $50,000 into Axsome Therapeutics after its IPO would be close to $1 million today, based on a 33.32% compound annual growth rate over that period.","The article states that in 2025, Axsome Therapeutics' revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity.","The article states Auvelity is currently the company's most critical growth driver.","The article states Auvelity could soon gain an important label expansion for agitation in Alzheimer's disease (AD).","The article states there are more than five million AD patients in the U.S. who suffer from agitation and that there are few treatment options.","The article states Axsome Therapeutics has phase 3 assets across several conditions and that it predicts peak sales of over $16 billion for its current lineup.","The article notes regulatory setbacks have occurred before and that similar challenges could delay clinical or commercial progress.","The article notes long-term uncertainty, including risks that newer medicines could erode market share and that some candidates may never earn approval."],"numeric_claims":[{"label":"IPO-to-now CAGR (article)","value":"33.32%"},{"label":"Hypothetical investment value (article)","value":"$50,000 -> close to $1 million"},{"label":"2025 revenue","value":"$638.5 million"},{"label":"2025 revenue YoY growth (article)","value":"66%"},{"label":"AD agitation patients in U.S. (article)","value":"more than 5 million"},{"label":"Predicted peak sales (article)","value":"over $16 billion"}],"primary_claim":"Axsome Therapeutics (AXSM) has delivered market-beating returns since its 2015 IPO, and the article suggests its pipeline and current products could drive growth for a while.","relevance_score":0.25,"sentiment":"mixed","source_quality":"high","summary":"The Motley Fool article discusses Axsome Therapeutics (NASDAQ: AXSM) and argues the stock has delivered strong returns since its 2015 IPO, citing clinical/regulatory progress and an approved-drug portfolio. It does not provide any unusual trading-volume metrics or a volume-vs-average ratio in the provided text.","topics":["biotech","stock performance since IPO","pipeline catalysts","Auvelity revenue growth","regulatory risk","label expansion","patent/exclusivity","investment recommendation framing"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsAxsome Therapeutics has performed well since its IPO.","tickers":[],"title":"Is This Healthcare Stock a Millionaire Maker?","url":"https://www.fool.com/investing/2026/04/08/is-this-healthcare-stock-a-millionaire-maker/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel